Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Congenital Adrenal Hyperplasia
- Main trialPhase 3
- “This phase III study is an open-label extension study to be conducted at approximately 21 investigational sites across 3 countries. The study will evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).”In the company’s words, NCT05299554 on ClinicalTrials.gov
Other drugs for Congenital Adrenal Hyperplasia
- AtumelnantCrinetics Pharmaceuticals Inc. · Phase 3
- CrinecerfontNeurocrine Biosciences · Phase 3
- NBIP-01435Neurocrine Biosciences · Phase 2
- BBP-631Adrenas Therapeutics Inc · Phase 1/2
- AsedebartH. Lundbeck A/S · Phase 2
- OMS1620OMass Therapeutics Australia Proprietary Ltd · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 15 Jan 2026 | Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026